Surgical bioprosthetic aortic valves made with bioengineered Resilia tissue (Edwards Lifesciences) appear to suffer less structural deterioration over 8 years compared with similar devices made of ...

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR ... including the Ultra and Ultra Resilia TAVR devices. The move followed positive data from the EARLY TAVR trial, reported ...

including the INSPIRIS RESILIA aortic surgical valve, the KONECT RESILIA aortic surgical valve conduit, the MITRIS RESILIA mitral surgical valve and the SAPIEN 3 Ultra RESILIA transcatheter aortic ...

Edwards Lifesciences (NYSE: EW) received FDA approval for its Sapien 3 TAVR for severe aortic stenosis (AS) without symptoms.

The company highlighted a study spanning eight years that compared the performance of surgical aortic valves made with its proprietary Resilia tissue to those without, showing reduced rates of ...

Edwards Lifesciences announced the FDA approved its transcatheter aortic valve replacement platform for treatment of severe ...

Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve ...

CAIRO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue ...

Edwards Lifesciences (EW) announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary Resilia tissue technology have significantly improved ...

The US Food and Drugs Administration ( FDA) has approved the Sapien 3 transcatheter aortic valve replacement (TAVR) system ...